Results 91 to 100 of about 8,771 (219)

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study [PDF]

Introduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial.
Alvarenga, José Miguel, Balato, Anna, Caccavale, Stefano, Carrascosa, Jose-Manuel, Chiricozzi, Andrea, Cruz, Maria João, Daponte, Athina Ioanna, Duarte, Bruno, Farinha, Pedro, Ferrucci, Silvia Mariel, Gkalpakiotis, Spyridon, Gori, Niccolò, Gregoriou, Stamatios, Herranz, Pedro, Kolios, Antonio, Lazaridou, Elizabeth, Marzano, Angelo Valerio, Munera-Campos, Monica, Ortoncelli, Michela, Paiva Lopes, Maria João, Peris, Ketty, Pires Rosa, Gilberto, Prajapati, Vimal H, Prignano, Francesca, Rankin, Brian D, Ribero, Simone, Rompoti, Natalia, Silvi, Gianmarco, Sood, Siddhartha, Torres, Tiago, Yeung, Jensen   +30 more
core   +1 more source

Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey

Rheumatology &Autoimmunity, EarlyView.
Haojie Xu, Liyun Zhang, Yuehong Huo, Rui Wu, Lijun Wu, Ling Lei, Linyu Geng, Chunyu Tan, Xiaomei Li, Ru Li, Yin Su, the Women's Rheumatoid Arthritis Research Collaborative Group   +11 more
wiley   +1 more source

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long‐term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy‐refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).
Christian Seebauer, Hans‐Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein   +5 more
wiley   +1 more source

Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE [PDF]

Introduction: This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheumatoid ...
Bassette, Louis, Blanco Alonso, Ricardo, Chan, Kelly, Fleischmann, Roy, Khan, Nasser, McDearmon-Blondell, Erin, Mysler, Eduardo, Penn, Sara K., Song, Yanna, Van den Bosch, Filip   +9 more
core  

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BMC Rheumatology, 2018
Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.
Julie M. Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S. Camp, Robert J. Padley, Jonathan S. George, Deborah Hyland, Matthew Rosebraugh, Neil Wishart, Lisa Olson, Andrew J. Long   +13 more
doaj   +1 more source

Can in vitro/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib [PDF]

Upadacitinib, classified as a highly soluble drug, is commercially marketed as RINVOQ®, a modified-release formulation incorporating hydroxypropyl methylcellulose as a matrix system to target extended release throughout the gastrointestinal (GI) tract ...
Alvarenga de Oliveira, M, Basit, AW, Favaron, A, Hens, B, McAllister, M, Montanha, M, Moustafa, S, Orlu, M, Tomaszewska, I   +8 more
core  

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data [PDF]

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD).
Alfredo Papa, Angelo Del Gaudio, Antonio Gasbarrini, Franco Scaldaferri, Gaetano Coppola, Jacopo Iaccarino, Loris Riccardo Lopetuso, Lucrezia Laterza, Pierluigi Puca, Stefania Colantuono, Valentina Blasi   +10 more
core   +1 more source

Dupilumab‐Associated Palmar Erythema Successfully Treated With Fluconazole

Australasian Journal of Dermatology, EarlyView.
Katina J. Selvaraj, Geoffrey Lee
wiley   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment [PDF]

Achieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments.
Corominas, Hèctor, Díaz Torne, César, Martinez-Molina, Cristina, Park, Hye S., Vidal, Silvia   +4 more
core   +1 more source